PDMR Notification

MGC Pharmaceuticals Limited

18 July 2023

 

MGC Pharmaceuticals Ltd.

PDMR Notification

18 July 2023

ASX, LSE: MXC

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') announces, further to the Company's "£0.7 million Fundraising" announcement on 14 July 2023, details of the participation of Persons Discharging Managerial Responsibilities ("PDMRs") in the Subscription in accordance with the UK Market Abuse regulations.

Full details of the shares subscribed by the PDMRs in the Subscription are contained in the disclosure tables below.

Capitalised terms not otherwise defined in this announcement shall have the same meaning ascribed to them in the Company's announcement made on 14 July 2023.

1	Details of the person discharging managerial responsibilities/person closely associated
(a)	Name		Amir Polak
2	Reason for the notification
(a)	Position		Chief Pharmaceutical Development Officer
(b)	Initial notification/amendment		Initial
(c)	If amendment: reason		n/a
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
	Full name of entity		MGC Pharmaceuticals Limited
	Legal Entity Identifier Code		213800HRE3FQJ6RK4H10
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
(a)	Description of the financial instrument, type of instrument		Fully Paid Ordinary Shares
(b)	Identification Code (ISIN)		AU000000MXC6
(c)	Nature of transaction		Shares issued following participation in fundraise
(d)	Currency	Price		Volume	Total
	GBP	£0.0012		4,416,667	£5,300
	Aggregated information
	GBP	£0.0012		4,416,667	£5,300
(e)	Date of transaction		14 July 2023
(f)	Place of transaction		Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
(a)	Name		Itay Nissim
2	Reason for the notification
(a)	Position		Chief Manufacturing and Supply Chain Officer
(b)	Initial notification/amendment		Initial
(c)	If amendment: reason		n/a
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
	Full name of entity		MGC Pharmaceuticals Limited
	Legal Entity Identifier Code		213800HRE3FQJ6RK4H10
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
(a)	Description of the financial instrument, type of instrument		Fully Paid Ordinary Shares
(b)	Identification Code (ISIN)		AU000000MXC6
(c)	Nature of transaction		Shares issued following participation in fundraise
(d)	Currency	Price		Volume	Total
	GBP	£0.0012		3,833,333	£4,600
	Aggregated information
	GBP	£0.0012		3,833,333	£4,600
(e)	Date of transaction		14 July 2023
(f)	Place of transaction		Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
(a)	Name		Yair Tal
2	Reason for the notification
(a)	Position		Chief Information Security Officer
(b)	Initial notification/amendment		Initial
(c)	If amendment: reason		n/a
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
	Full name of entity		MGC Pharmaceuticals Limited
	Legal Entity Identifier Code		213800HRE3FQJ6RK4H10
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
(a)	Description of the financial instrument, type of instrument		Fully Paid Ordinary Shares
(b)	Identification Code (ISIN)		AU000000MXC6
(c)	Nature of transaction		Shares issued following participation in fundraise
(d)	Currency	Price		Volume	Total
	GBP	£0.0012		2,166,667	£2,600
	Aggregated information
	GBP	£0.0012		2,166,667	£2,600
(e)	Date of transaction		14 July 2023
(f)	Place of transaction		Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
(a)	Name		Yifat Steuer
2	Reason for the notification
(a)	Position		Chief Operating Officer and Deputy CEO
(b)	Initial notification/amendment		Initial
(c)	If amendment: reason		n/a
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
	Full name of entity		MGC Pharmaceuticals Limited
	Legal Entity Identifier Code		213800HRE3FQJ6RK4H10
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
(a)	Description of the financial instrument, type of instrument		Fully Paid Ordinary Shares
(b)	Identification Code (ISIN)		AU000000MXC6
(c)	Nature of transaction		Shares issued following participation in fundraise
(d)	Currency	Price		Volume	Total
	GBP	£0.0012		5,833,333	£7,000
	Aggregated information
	GBP	£0.0012		5,833,333	£7,000
(e)	Date of transaction		14 July 2023
(f)	Place of transaction		Outside a trading venue

--Ends--

Authorised for release by the Managing Director, for further information please contact:

MGC Pharmaceuticals Ltd      Roby Zomer CEO & Managing Director [phone] [e-mail]	MGC Pharmaceuticals Ltd Arron Canicais / Rowan Harland Joint Company Secretaries [phone] [e-mail]
UK Brokers Peterhouse Capital Charles Goodfellow / Lucy Williams / Duncan Vasey [phone] [e-mail]	UK Brokers Oberon Capital Adam Pollock / Aimee McCusker [phone] [e-mail] [e-mail]
UK IR/PR Advisers IDC Advisory Graham Herring / Tim Metcalfe / Zach Cohen [e-mail]

 

END